Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502202 | 0.83 | TPMT (0.62) | TPMTHCAR1CES2CES1HPGD | |
| SCHEMBL2170895 | 0.83 | TPMT (0.62) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL29912669 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL2172133 | 0.82 | TPMT (0.70) | TPMTKDRHCAR1CNR2HCAR2 | |
| SCHEMBL668260 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL12372142 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL22383502 | 0.80 | PARP1 (0.50) | TPMTKDRHCAR1CES2CES1 | |
| Hydrochloric Acid SCHEMBL29111199 | 0.80 | TPMT (0.67) | TPMTKDRHCAR1CNR2HCAR2 | |
| SCHEMBL14110107 | 0.80 | TPMT (0.43) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL11526256 | 0.80 | PARP1 (0.50) | TPMTKDRHCAR1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2346883-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Traversa Therapeutics, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010039543-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885KDR 3240/4885HCAR1 4112/4885 |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885KDR 3240/4885HCAR1 4112/4885 |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | TPMT 3047/4885KDR 2225/4885HCAR1 4052/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | TPMT 3886/4885KDR 3240/4885HCAR1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.